Shafik N Wassef1,2, John Wemmie3,4,5, Casey P Johnson1, Hans Johnson2, Jane S Paulsen3,6,7, Jeffrey D Long3,8, Vincent A Magnotta1,3,9. 1. Department of Radiology, University of Iowa, Iowa City, Iowa, USA. 2. SINAPSE, Iowa Neuroimaging Consortium, Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA. 3. Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA. 4. Department of Neurosurgery, University of Iowa, Iowa City, Iowa, USA. 5. Veterans Affairs Hospital Center, Iowa City, IA, USA. 6. Department of Neurology, University of Iowa, Iowa City, Iowa, USA. 7. Department of Psychology, University of Iowa, Iowa City, Iowa, USA. 8. Department of Biostatistics, University of Iowa, Iowa City, Iowa, USA. 9. Department of Biomedical Engineering, University of Iowa, Iowa City, Iowa, USA.
Abstract
BACKGROUND: Imaging biomarkers sensitive to Huntington's disease (HD) during the premanifest phase preceding motor diagnosis may accelerate identification and evaluation of potential therapies. For this purpose, quantitative MRI sensitive to tissue microstructure and metabolism may hold great potential. We investigated the potential value of T1ρ relaxation to detect pathological changes in premanifest HD (preHD) relative to other quantitative relaxation parameters. METHODS: Quantitative MR parametric mapping was used to assess differences between 50 preHD subjects and 26 age- and sex-matched controls. Subjects with preHD were classified into two progression groups based on their CAG-age product (CAP) score; a high and a low/moderate CAP group. Voxel-wise and region-of-interest analyses were used to assess changes in the quantitative relaxation times. RESULTS: T1ρ showed a significant increase in the relaxation times in the high-CAP group, as compared to controls, largely in the striatum. The T1ρ changes in the preHD subjects showed a significant relationship with CAP score. No significant changes in T2 or T2* relaxation times were found in the striatum. T2* relaxation changes were found in the globus pallidus, but no significant changes with disease progression were found. CONCLUSION: These data suggest that quantitative T1ρ mapping may provide a useful marker for assessing disease progression in HD. The absence of T2 changes suggests that the T1ρ abnormalities are unlikely owing to altered water content or tissue structure. The established sensitivity of T1ρ to pH and glucose suggests that these factors are altered in HD perhaps owing to abnormal mitochondrial function.
BACKGROUND: Imaging biomarkers sensitive to Huntington's disease (HD) during the premanifest phase preceding motor diagnosis may accelerate identification and evaluation of potential therapies. For this purpose, quantitative MRI sensitive to tissue microstructure and metabolism may hold great potential. We investigated the potential value of T1ρ relaxation to detect pathological changes in premanifest HD (preHD) relative to other quantitative relaxation parameters. METHODS: Quantitative MR parametric mapping was used to assess differences between 50 preHD subjects and 26 age- and sex-matched controls. Subjects with preHD were classified into two progression groups based on their CAG-age product (CAP) score; a high and a low/moderate CAP group. Voxel-wise and region-of-interest analyses were used to assess changes in the quantitative relaxation times. RESULTS: T1ρ showed a significant increase in the relaxation times in the high-CAP group, as compared to controls, largely in the striatum. The T1ρ changes in the preHD subjects showed a significant relationship with CAP score. No significant changes in T2 or T2* relaxation times were found in the striatum. T2* relaxation changes were found in the globus pallidus, but no significant changes with disease progression were found. CONCLUSION: These data suggest that quantitative T1ρ mapping may provide a useful marker for assessing disease progression in HD. The absence of T2 changes suggests that the T1ρ abnormalities are unlikely owing to altered water content or tissue structure. The established sensitivity of T1ρ to pH and glucose suggests that these factors are altered in HD perhaps owing to abnormal mitochondrial function.
Authors: Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn Journal: Lancet Neurol Date: 2011-12-02 Impact factor: 44.182
Authors: Julia A Rao; Deborah L Harrington; Sally Durgerian; Christine Reece; Lyla Mourany; Katherine Koenig; Mark J Lowe; Vincent A Magnotta; Jeffrey D Long; Hans J Johnson; Jane S Paulsen; Stephen M Rao Journal: Cortex Date: 2014-06-02 Impact factor: 4.027
Authors: S E Browne; A C Bowling; U MacGarvey; M J Baik; S C Berger; M M Muqit; E D Bird; M F Beal Journal: Ann Neurol Date: 1997-05 Impact factor: 10.422
Authors: Eve M Dumas; Maarten J Versluis; Simon J A van den Bogaard; Matthias J P van Osch; Ellen P Hart; Willeke M C van Roon-Mom; Mark A van Buchem; Andrew G Webb; Jeroen van der Grond; Raymund A C Roos Journal: Neuroimage Date: 2012-03-28 Impact factor: 6.556
Authors: Nellie Georgiou-Karistianis; Julie C Stout; Juan F Domínguez D; Sarah P Carron; Ayaka Ando; Andrew Churchyard; Phyllis Chua; India Bohanna; Alicia R Dymowski; Govinda Poudel; Gary F Egan Journal: Hum Brain Mapp Date: 2013-08-02 Impact factor: 5.038
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: Nana Owusu; Casey P Johnson; William Kearney; Dan Thedens; John Wemmie; Vincent A Magnotta Journal: NMR Biomed Date: 2019-11-19 Impact factor: 4.044
Authors: Amro Saad Aldine; Amy Ogilvie; John Wemmie; James Kent; Jordan Schultz; Jeffrey D Long; John Kamholz; Hassan Sajjad; Joel Kline; Emily Shaw; Michelle Voss; Jane S Paulsen; Vincent A Magnotta Journal: SVOA Neurol Date: 2021-02-03
Authors: Laura L Boles Ponto; Vincent A Magnotta; Yusuf Menda; David J Moser; Jacob J Oleson; Emily L Harlynn; Sean D DeVries; John A Wemmie; Susan K Schultz Journal: J Neuropsychiatry Clin Neurosci Date: 2020-04-14 Impact factor: 2.198
Authors: Alexander V Tereshchenko; Jordan L Schultz; Ansley J Kunnath; Joel E Bruss; Eric A Epping; Vincent A Magnotta; Peg C Nopoulos Journal: Brain Sci Date: 2020-08-08
Authors: Joseph J Shaffer; Merry Mani; Samantha L Schmitz; Jia Xu; Nana Owusu; Dee Wu; Vincent A Magnotta; John A Wemmie Journal: Front Psychiatry Date: 2020-09-24 Impact factor: 4.157
Authors: Matthew J Sodoma; Rachel C Cole; Taylor J Sloan; Chase M Hamilton; James D Kent; Vincent A Magnotta; Michelle W Voss Journal: Neuroimage Date: 2021-10-30 Impact factor: 6.556